The Technology
Lymphocyte Activation Gene 3 (LAG-3) is an immune checkpoint receptor that plays a critical role in regulating immune responses. While extensively studied in cancer immunotherapy, new research reveals that LAG-3 directly binds to influenza virus hemagglutinin (HA), suppressing antiviral immune responses. This novel antibody specifically targets the LAG-3-HA interaction, enhancing CD8+ T cell activation and improving immune response against influenza. Additionally, since LAG-3 is implicated in autoimmune diseases through its glycosylated domain, blocking this interaction could restore immune balance in various inflammatory and immune-mediated conditions. By targeting the glycan-dependent interaction of LAG-3, this antibody approach aims to improve immune responses in both viral infections and autoimmune diseases while preserving immune system integrity.
LAG-3 antibody represents a novel strategy to enhance antiviral immunity while offering a new therapeutic approach for autoimmune diseases.
Advantages
- Enhances antiviral immunity by preventing LAG-3-mediated suppression of CD8+ T cell responses
- Potential for broad-spectrum antiviral treatment by targeting multiple influenza strains
- Reduces autoimmune suppression by modulating LAG-3’s interaction with immune-regulating ligands
- Monoclonal antibody approach ensures high specificity and therapeutic efficacy
Applications and Opportunities
- Novel antibody-based Influenza treatment, enhancing immune response against seasonal and pandemic influenza strains
- Autoimmune disease therapy
- Broader infectious disease applications: potential to extend research to other viral infections exploiting LAG-3 for immune evasion
Business Development Contacts